Cullinan Oncology LLC’s shares reached a 52-week high of $23.07 on Tuesday, extending a strong rally driven by clinical progress in its oncology pipeline. The stock closed at $22.95 on Aug. 25, up 5.18% for the session, according to market data.
The biotech firm, which trades under the ticker CGEM, has surged roughly 200% over the past 12 months and posted a year-to-date gain of 122%, reflecting investor optimism tied to its drug development programs. UBS maintained its Buy rating but raised its price target to $27 from a prior level, citing the company’s advancing clinical programs and potential in targeted cancer therapies.
Cullinan’s lead asset, zipalertinib, demonstrated a significant progression-free survival benefit in combination with chemotherapy in the Phase 3 REZILIENT3 trial for non-small cell lung cancer patients. The company also highlighted progress on CLN-049, a drug targeting acute myeloid leukemia, after receiving favorable feedback from U.S. regulators. Cullinan plans to initiate a Phase 2 study for CLN-049 in the third quarter of 2026.
Additional pipeline updates included clinical data presentations for autoimmune drug candidates CLN-978 and velinotamig at an Immunology Day event in New York, where William Blair reiterated an Outperform rating. CLN-978 targets systemic lupus erythematosus and lupus nephritis, while velinotamig is being developed for broader autoimmune indications.
Corporate governance changes were also announced during Cullinan’s Annual Meeting of Stockholders, where two Class III directors were elected to three-year terms. The company’s market capitalization stands at approximately $1.48 billion as of the latest trading session.
